Endocrine Abstracts

Enhanced Community Care (ECC) for type 2 diabetes mellitus (T2DM) is a new initiative in Ireland. The goals of this study were to evaluate changes in clinical parameters amongst patients attending the Dublin North West (DNW) Diabetes hub, Ireland’s first fully-operational ECC hub. This was a retrospective observational study of consecutive new patients attending the DNW hub for consultant-led T2DM care between March 2023-2024. The study assessed changes in biochemical markers and T2DM medications from first presentation to time of discharge from the hub or the most recent clinic visit. In total, 146 patients with T2DM attended the hub service and provided data at first presentation along with data from at least one subsequent follow-up visit. Mean age of the participants was 55.6±12 years, 79 (54%) male. Mean duration of follow-up was 13.9±5.5 months. While attending the hub, mean HbA1c decreased from 62.4±19.7 to 50±11.8 mmol/l/mol (P < 0.01), mean total cholesterol decreased from 4.5±1.1 to 4.0±0.9 mmol/l/l(P < 0.01) and mean LDL decreased from 2.5±0.9 to 2.0±0.8 mmol/l/l(P < 0.01). Use of GLP-1 receptor agonists increased from 12.1% (n = 17) at first visit to 42.9% (n = 60) at discharge/most recent visit, while SGLT 2 inhibitor use increased from 26.4% (n = 37) to 60.0% (n = 84). Significant improvements in HbA1c and lipids were observed following attendance at the hub T2DM services. These preliminary findings suggest that community-based T2DM services may help to optimise diabetes care.